<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50849">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444234</url>
  </required_header>
  <id_info>
    <org_study_id>HS-15-00182</org_study_id>
    <nct_id>NCT02444234</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis</brief_title>
  <official_title>Steady-State Pharmacokinetics of Tedizolid in Plasma and Sputum of Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is designed to characterize the pharmacokinetics of intravenous and oral
      tedizolid in patients with Cystic Fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent epidemiological studies have demonstrated that the presence of methicillin-resistant
      Staphylococcus aureus (MRSA) in the airways of patients with CF is associated with more
      rapid lung function decline and a higher mortality. Tedizolid is a new antibiotic with
      potent activity against MRSA. Tedizolid is currently FDA approved for treatment of skin soft
      tissue infections with MRSA. The proposed study is designed to characterize the
      pharmacokinetics of intravenous and oral tedizolid in patients with CF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Sputum Concentration</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the sputum concentration versus time curve (AUC)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Sputum Concentration (Tmax)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Tedizolid PO/IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tedizolid phophate 200mg tablet with crossover to IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tedizolid IV/PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tedizolid phophate 200mg IV with crossover to PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tedizolid PO/IV</intervention_name>
    <description>Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.</description>
    <arm_group_label>Tedizolid PO/IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tedizolid IV/PO</intervention_name>
    <description>Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.</description>
    <arm_group_label>Tedizolid IV/PO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CF based on positive sweat chloride or known CF mutation

          -  Age &gt; 17 years

          -  Able to spontaneously expectorate sputum

        Exclusion Criteria:

          -  Any clinically significant laboratory abnormalities

          -  Presence of an ongoing acute pulmonary exacerbation

          -  Pregnancy

          -  Serious past allergy to linezolid or tedizolid

          -  No alcohol, nicotine, or caffeine-containing products during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean Chan</last_name>
    <phone>(323) 442-2825</phone>
    <email>jeanbcha@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soheil Jadali</last_name>
    <phone>323-442-7277</phone>
    <email>sjadali@research.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Beringer, PharmD</last_name>
      <phone>323-442-1402</phone>
      <email>beringer@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lynn Fukushima, R.N.</last_name>
      <phone>323-442-8522</phone>
    </contact_backup>
    <investigator>
      <last_name>Adupa P Rao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>May 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Beringer</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Torezolid</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
